Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. by Hou, Liping et al.
UC San Diego
UC San Diego Previously Published Works
Title
Genetic variants associated with response to lithium treatment in bipolar disorder: a 
genome-wide association study.
Permalink
https://escholarship.org/uc/item/54w31580
Journal
Lancet (London, England), 387(10023)
ISSN
0140-6736
Authors
Hou, Liping
Heilbronner, Urs
Degenhardt, Franziska
et al.
Publication Date
2016-03-01
DOI
10.1016/s0140-6736(16)00143-4
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Genetic variants associated with response to lithium treatment 
in bipolar disorder: a genome-wide association study
This manuscript version is made available under the CC BY-NC-ND 4.0 license.
#Corresponding authors: Thomas G. Schulze, MD, Institute of Psychiatric Phenomics and Genomics (IPPG), Medical Center of the 
University of Munich, Campus Innenstadt, Nußbaumstr. 7, 80336 München, GERMANY, Tel.: +49-(0)89 4400 55568, Fax: +49-(0)89 
4400 55562, tschulze@med.lmu.de, Francis J. McMahon, MD, Human Genetics Branch and Genetic Basis of Mood and Anxiety 
Disorders Section, National Institute of Mental Health Intramural Research Program, 35 Convent Drive, Rm 1A202, Bethesda, MD 
20892-3719, USA, Tel.: +1-301-451-4453, Fax: +1- 301-402-9081, mcmahonf@mail.nih.gov.
*These authors contributed equally
Declaration of interests
Adli M has received a grant from Servier, speaker’s fees from Servier, Lundbecck, Aristo, Parexel, Gilead, ViiV, and Deutsche Bank 
plus a non-financial support from Lundbeck. Akiyama K has received speaker’s fees from Taisho Toyama Pharmaceutical. Alda M is 
funded by a grant of the Canadian Institutes of Health Research. Bauer M has received speaker’s fees from Alkermes, Astra Zeneca, 
BristolMyersSquibb, and Ferrer Internacional. Etain B received non-financial support from Labex Biopsy and Fondation Fondamental. 
Hashimoto R received grants and speaker honoraria from Dainippon Sumitomo Pharma and Novartis plus speaker honoraria from Eli 
Lilly Japan, GlaxoSmithKline, Hisamitsu Pharmaceutical, Janssen Pharmaceutical, Nippon Zoki Pharmaceutical, Otsuka 
Pharmaceutical, Astellas Pharma, Pfizer, and the Yoshitomiyakuhin Corporation. Kato T received a grant from Takeda Pharmaceutical 
and fees from Kyowa Hakko Kirin, Eli Lilly Japan, Otsuka Pharmaceutical, GlaxoSmithKline, Taisho Toyama Pharmaceutical, 
Dainippon Sumitomo Pharma, Meiji Seika Pharma, Pfizer Japan, Mochida Pharmaceutical, Shionogi & Co, Janssen Pharmaceutical, 
Yoshitomiyakuhin Corporation, Agilent Technologies, Astellas Pharma, and Wako Pure Chemical Industries. Kusumi I received grants 
and fees from Dainippon Sumitomo Pharma, Eisai, Eli Lilly, GlaxoSmithKline, Kyowa Hakko Kirin, Meiji Seika Pharma, MSD, 
Novartis, Otsuka, Ono Pharmaceutical, Pfizer, Tanabe Mitsubishi Pharma, Takeda Pharmaceutical, Shionogi, and Yoshitomi 
Pharmaceutical; he received grants from AbbVie GK, Asahi Kasei Pharma, Boehringer Ingelheim, Chugai Pharmaceutical, and 
Daiichi Sankyo and fees from Astellas Pharma and Janssen Pharmaceutical. McCarthy MJ served as unpaid consultant for Pathway 
Genomic (San Diego, USA). McElroy received a grant and fees from Naurex and Shire, further grants from Alkermes, Cephalon, 
Forest, Marriott Foundation, Orexigen Therapeutics, and Takeda Pharmaceutical, he further has served on the advisory boards for 
Bracket, Hoffmann-La Roche, MedAvante, Sunovion and received fees from Novo Nordisk. Perlis RH received personal fees from 
RID Ventures, Genomind LLC, Healthrageous, Pfizer, Perfect Health, Proteus and Psybrain. Schofield PR received a grant from 
NHMRC. Schulze TG received a grant and fees from Roche Pharmaceuticals. Stamm TJ received personal fees from Servier, 
Lundbeck and BristolMyerSquibb. All above listed interests are outside of the submitted work. All other authors declare no conflict of 
interests.
Contributors
Hou L, Heilbronner U, Degenhardt F, Alda M, Rietschel M, McMahon FJ, and Schulze TG designed the study, contributed to analysis 
and interpretation of data and wrote the first draft of the manuscript. Akula N, Chen HC, Cichon S, Forstner AJ, Frye MA, Herms S, 
Hoffman P, Jamain S, Mattheisen M, Nöthen M, Shekhtman T, Wray NR, and Zandi PP provided further data analyses. Hou L did the 
statistical analyses and prepared the tables and figures. Adli M, Akula N, Alda M, Bauer M, Cichon S, Czersiki P, Degenhardt F, Del 
Zompo M, Hauser J, Heilbronner U, Landén M, McMahon FJ, Hou L, Perlis RH, Reininghaus E, Rietschel M, Rybakowski JK, 
Schalling M, Schofield PR, Schulze TG, Shilling PD, Smoller JW, Squassina A were responsible for study design. Responsible for 
patient recruitment were Adli M, Akiyama K, Alda M, Ardau R, Arias B, Aubry JM, Backlund L, Banzato EM, Bauer M, Baune BT, 
Bellivier F, Benabarre A, Colom F, Jiménez E, Vieta E, Bengesser SA, Bhattacharjee AK, Birner A, Cervantes P, Chilotti C, Clark SR, 
Cruceanu C, Czerski P, Dayer A, Del Zompo M, DePaulo JR, Etain B, Falkai P, Frisén L, Frye MA, Fullerton JM. Gard S, Garnham J. 
Goes FS, Grigoroiu-Serbanescu M, Grof P, Gruber O, Hashimoto R, Hauser J, Jamain S, Jiménez E, Kahn JP, Kassem L, Kato T, 
Kelsoe J, Reif A, Kittel-Schneider S, Volkert J, Kliwicki S, König B, Kuo PH, Kusumi I, Lackner N, Laje G, Landén M, Leboyer M, 
Leckband SG, MacQueen G, Maj M, Manchia M, Martinsson L, McElroy SL, Mitchell PB, Mitjans M, Mondimore FM, Monteleone 
P, Novak T, Ösby U, Ozaki N, Pfennig A, Potash J, Reich-Erkelenz D, Reininghaus E, Rietschel M, Rouleau GA, Rybakowski JK, 
Schofield PR, Schubert KO, Schulze TG, Schweizer B, Severino G, Shilling PD, Shimoda K, Simhandl C, Slaney C, Stamm TJ, 
Stopkova P, Tighe SK, Tortorella A, Turecki G, Witt S, Wright A, Young TL, and Zandi PP. Patient in-depth phenotyping was carried 
out by Adli M, Akiyama K, Alda M, Ardau R, Arias B, Backlund L, Bauer M, Baune BT, Bellivier F, Benabarre A, Colom F, Jiménez 
E, Vieta E, Bengesser SA, Birner A, Brichant-Petitjean C, Bui E, Chilotti C, Cruceanu C, Dantas CR, Del Zompo M, DePaulo JR, 
Frye MA, Goes FS, Grigoroiu-Serbanescu M, Grof P, Hashimoto R, Jiménez E, Kassem L, Kliwicki S, Kuo PH, Lackner N, Landén 
M, and Lavebratt C. All authors contributed to drafting the work or revising it critically for important intellectual content and made 
substantial contributions to the concept and design of the study and acquisition, analysis and interpretation of data.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Lancet. Author manuscript; available in PMC 2017 March 12.
Published in final edited form as:
Lancet. 2016 March 12; 387(10023): 1085–1093. doi:10.1016/S0140-6736(16)00143-4.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A full list of authors and affiliations appears at the end of the article.
Abstract
Background—Lithium remains a first-line treatment in bipolar disorder, but individual response 
is variable. Previous studies have suggested that lithium response is a heritable trait. However, no 
genetic markers have been reproducibly identified.
Methods—Here we report the results of a genome-wide association study of lithium response in 
2,563 patients collected by 22 participating sites from the International Consortium on Lithium 
Genetics (ConLiGen); the largest attempted so far. Data from over 6 million common single 
nucleotide polymorphisms (SNPs) were tested for association with categorical and continuous 
ratings of lithium response of known reliability.
Findings—A single locus of four linked SNPs on chromosome 21 met genome-wide significance 
criteria for association with lithium response (rs79663003: p=1·37×10−8; rs78015114: 
p=1·31×10−8; rs74795342: p=3·31×10−9; rs75222709: p=3·50×10−9). In an independent, 
prospective study of 73 patients treated with lithium monotherapy for a period of up to two years, 
carriers of the response-associated alleles had a significantly lower rate of relapse than carriers of 
the alternate alleles (p=0·03, hazard ratio = 3·8).
Interpretation—The response-associated region contains two genes coding for long non-coding 
RNAs (lncRNAs), AL157359.3 and AL157359.4. LncRNAs are increasingly appreciated as 
important regulators of gene expression, particularly in the CNS. Further studies are needed to 
establish the biological context of these findings and their potential clinical utility. Confirmed 
biomarkers of lithium response would constitute an important step forward in the clinical 
management of bipolar disorder.
INTRODUCTION
Bipolar disorder (BD) is an often devastating psychiatric illness characterized by disruptive 
mood swings, with intervals of partial or full recovery. BD type I and II affect at least 2% of 
the world’s population; subthreshold forms afflict another 2%1. BD consumes a substantial 
portion of mental health resources. Worldwide, the direct and indirect costs are large, with 
an estimated US$151 billion spent in the US alone in 20092. Moreover, up to 15% of 
sufferers die by suicide3.
Mood stabilizers are a primary mode of medication treatment for BD4. Among these drugs, 
lithium stands out as a preventive agent for manic episodes5 and suicide6. Consequently, 
lithium is still recommended as a first-line treatment for BD, even though individual 
response is variable. Many patients show a robust improvement with lithium and a subset is 
highly responsive7–9, with near total resolution of symptoms. On the other hand, at least 
30% of patients are only partially responsive, and more than 30% have no clinical response 
to lithium.
Evidence suggests that some of the variability in lithium response has a genetic basis, but 
sample sizes in such studies have been limited. Good responders are more likely to have a 
family history of BD than poor responders10. Patients who stabilized on lithium tend to 
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aggregate within families11, 12. A twin study reported better lithium prophylaxis in twins 
whose co-twin also had BD13.
Genetic markers of lithium response could provide insight into the biological mechanism of 
lithium action and might be valuable for treatment planning. However, few pharmacogenetic 
studies of lithium have been published, and those have generally employed small samples 
and variable definitions of response. Candidate gene studies have focused on genes 
purported to be involved in the therapeutic action of lithium, but replicable results have not 
emerged14, 15. Three genome-wide association studies (GWAS) of lithium response have 
been published. The first was from the Systematic Treatment Enhancement Program for 
Bipolar Disorder (STEP-BD) cohort16, in which 458 BD-I/II patients were treated with 
lithium and response was evaluated as time to recurrence during lithium treatment. No 
genome-wide significant results were identified. A second GWAS17 was carried out in 204 
Sardinian BD patients (only 52 were genotyped with SNP arrays). No SNPs reached 
genome-wide significance. Most recently, Chen and colleagues18 performed a GWAS on 
294 highly treatment adherent individuals of Asian ancestry selected from a larger set of 
about 2000 treated for BD-I with lithium monotherapy. The authors reported genome-wide 
significant association with a cluster of SNPs at 3p24.1. However, to date, all reported 
studies have failed to replicate these findings in either Asian or European ancestry 
samples19–21.
In order to overcome the problems inherent in smaller sample sizes, we established the 
international Consortium on Lithium Genetics (www.ConLiGen.org) in 200822. Here we 
report the results of an initial GWAS of lithium response in 2563 BD patients – by far the 
largest sample to date – using phenotype and genotype data from 22 ConLiGen sites from 
four continents (Europe, America, Asia and Australia; for details, see Table S1; 
Supplementary Materials). The Taiwanese sample included is independent from the sample 
studied by Chen and colleagues18. Four linked SNPs met genome-wide significance criteria 
for association with a quantitative measure of lithium response. The associated locus has 
been annotated with two long, non-coding RNA (lncRNA) genes. If replicated, these 
findings would constitute a novel genetic marker and could implicate lncRNAs in the 
mechanism of lithium response.
MATERIALS AND METHODS
Participants
Written informed consent was obtained from all participants. Study sites were largely non-
overlapping (Table S1; Supplementary Materials). Over the timeframe of this study 
(phenotyping between 2008 and 2013), available samples were collected and genotyped in 
two distinct phases. We thus analyzed the data as two distinct GWAS, referred to herein as 
‘GWAS 1’ and ‘GWAS 2’ (for a detailed rationale, see Supplementary Materials). The 
analysis pipeline is shown in Figure S1 (Supplementary Materials). Briefly, a total of 3193 
participants were genotyped; 2935 remained after quality control (QC).
A DSM-III or DSM-IV diagnosis of a bipolar spectrum disorder (see Supplementary 
Materials) was required, along with data on gender and total score on the Alda scale (see 
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below). We included all patients in whom response could be reliably evaluated: patients 
were required to have taken lithium for a minimum of 6 months with no additional mood 
stabilizer added. Comorbid conditions were not among the exclusion criteria. After this step, 
1162 individuals were included in GWAS 1 and 1401 were included in GWAS 2.
Phenotypes
We used the “Retrospective Criteria of Long-Term Treatment Response in Research Subjects 
with Bipolar Disorder” (Alda scale12) for the evaluation of long-term treatment response to 
lithium. This scale measures the change in illness episodes in the course of treatment with 
lithium. Briefly, the Alda scale quantifies symptom improvement in the course of treatment 
(A score, range 0–10), which is then weighted against five criteria (B score) that assess 
confounding factors, each scored 0, 1 or 2. The total score is then derived by subtracting the 
total B score from the A score. Negative scores are set to 0 by default so that the total score 
ranges from 0 to 10.
ConLiGen previously conducted a multi-stage inter-rater reliability study23 aimed at finding 
the optimal way in which Alda subscale values can be combined for response evaluation. We 
evaluated two main phenotypes for lithium response: a dichotomous phenotype (good/poor 
response to lithium), that has been successfully used in previous studies9, 13, and a 
continuous phenotype (range 0 to 10). We found the most reliable dichotomous phenotype to 
be that which designated all subjects with a total score ≥ 7 as “responders”. The most 
reliable continuous phenotype was found to be one that used the A score but excluded all 
subjects with a total B score > 4. Descriptive statistics of the phenotypes of the total sample 
analyzed in the present study can be found in Table 1; excluded participants are detailed in 
Table S2 (Supplementary Materials).
Genotyping, quality control and imputation
DNA was extracted from peripheral blood samples. Samples were genotyped at the NIMH, 
Life & Brain Center at the University of Bonn, or Broad Institute using either Affymetrix or 
Illumina SNP arrays (Table S1; Supplementary Materials), according to the manufacturers’ 
protocols.
Quality control and imputation were carried out in batches corresponding to distinct SNP 
arrays and ethnicities. Six batches of data were used in GWAS 1, including five of European 
ancestry (Affymetrix 6·0, Human610/660W, HumanOmniExpress, HumanOmni1-Quad, 
HumanOmni2.5), and one of Japanese ancestry (HumanOmni2.5). Five batches of data were 
used in GWAS2, including four European-ancestry data sets (Affymetrix 6·0, Human660W, 
HumanOmni1-Quad, HumanOmniExpress), and one Taiwanese data set 
(HumanOmniExpress) not overlapping with the sample studied by Chen and colleagues18. 
Quality control parameters for retaining SNPs and subjects, including relatedness checking 
and population stratification analysis are detailed in the Supplementary Materials.
Genotype imputation was performed using the prephasing/imputation strategy24 
implemented by SHAPEIT225 and minimac26. The full 1000 Genomes Project data set was 
used as the reference panel. Imputation was performed separately for each SNP array and 
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ancestry group. Gene dosages for all markers with imputation r2 ≥ 0.5 in all batches were 
used for the final association tests.
Statistical analysis
Association testing was carried out separately in European-ancestry and Asian-ancestry 
samples. We analyzed both the categorical and quantitative response phenotypes. Using 
PLINK v1·0727, the association between allele dosages and the dichotomous phenotype was 
evaluated by logistic regression and the association between allele dosages and the 
quantitative phenotype was evaluated by linear regression. Genotyping platform was used as 
a covariate and, in the European-ancestry samples, the first four principal components of 
population structure were also included in the model to control for population stratification 
(Supplementary Materials). Site of collection was not included as a covariate because it was 
highly co-linear with genotyping platform. Results across GWAS 1 and GWAS 2 were 
combined by meta-analysis using METAL28, under a fixed-effects model with heterogeneity 
testing.
Overall results in GWAS 1 were compared to those in GWAS 2 by use of the Sign Test 
(Supplementary Materials). If there were no association between SNPs and traits, the 
expectation is that 50% of the β coefficients would have the same sign. The significance of 
the observed proportion was evaluated under the binomial distribution. To investigate the 
contribution of the BD risk profile scores (RPS) to lithium response, we used the LD 
clumped complete result file of 108 835 SNPs from the PGC bipolar GWAS29 to calculate –
log (OR) weighted RPS in each of the two European ancestry samples. Regression was then 
used to test whether the calculated RPS scores had any effect on the association between 
SNP dosages and lithium response by adding the RPS scores as an additional covariate in 
the regression model.
ROLE OF THE FUNDING SOURCES
The funding bodies had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. LH, UH, FJM, and TGS had full access to all the 
data. The corresponding authors FJM and TGS had final responsibility for the decision to 
submit for publication.
RESULTS
Our principal goal was to identify common genetic variants associated with differential 
response to lithium. Neither GWAS 1 nor GWAS 2 alone detected a genome-wide 
significant (p<5×10−8) result. However, there was greater than chance consistency between 
GWAS 1 and GWAS 2 in the overall direction of association. For the continuous phenotype, 
of 606 independent SNPs in GWAS 1 with p<0·001, 326 (54%) had the same sign in GWAS 
2. This represents a significantly greater agreement than chance alone (p=0·028). For the 
dichotomous phenotype, of 555 independent SNPs in GWAS 1 with p<0·001, 317 (57%) had 
the same sign in GWAS 2, significantly (p=0·0003) greater than chance (for the complete list 
of SNPs used in this test, see Table S4, Supplementary Materials).
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When both studies were combined by meta-analysis, genome-wide significance was attained 
for the continuous phenotype (Figures 1–3). Table 2 summarizes the top results (p<1×10−6) 
with the continuous phenotype (see Table S5 for the top results with the dichotomous 
phenotype). A region on chromosome 21 contained four SNPs that showed genome-wide 
significant association with lithium response (Figure 2) (minimum p=3·31×10−9). These four 
SNPs are in very strong LD with each other and have similar minor allele frequencies. The 
same 4 SNPs were associated with the dichotomous definition of lithium response at a 
p~0·01. These four SNPs also reached significance when only the European-ancestry 
population was considered (Table 2). The imputation quality for these 4 SNPs was excellent 
and was supported by direct genotyping in a subset of the total sample (see assay validation 
on page 2 of Supplementary Materials and Table S3).
The associated chromosomal region contains no known protein coding genes. Two lncRNAs 
have been identified in the region, ENSG00000232193 (AL157359.4) and 
ENSG00000226204 (AL157359.3). Two of the SNPs (rs74795342 and rs75222709) are 
located in the intronic region of the gene, AL157359.3. The other two SNPs (rs79663003 
and rs78015114) lie between these two lncRNA genes.
In the smaller Asian-ancestry samples, only rs7833426 on chromosome 8 had a p-value 
<10−6. This SNP lies within an intron of GFRA2, which codes for a glial cell line-derived 
neurotrophic factor (GDNF) receptor. This SNP did not pass QC in the European samples 
due to a minor allele frequency < 5%.
When the GWAS 1 and GWAS 2 were meta-analyzed under the dichotomous phenotype 
definition, there were no genome-wide significant results (Figure 1). The SNP with the 
lowest p-value (p=8·10×10−7) lies near an annotated lncRNA (ENSG00000258081) on 
chromosome 14 (Table S5, Supplementary Materials).
We calculated the power of this study to detect the observed association findings under an 
additive genetic model using Quanto (v1.2.4, http://biostats.usc.edu/Quanto.html). The 
sample had ~65% power to detect the reported association signal at an alpha of 5·0×10−8. 
For the dichotomous trait, however, the sample size still lacked power to identify genome-
wide significant association, even for common SNPs (MAF=0·2) with relatively large effect 
sizes (OR=2).
It is possible that lithium response is related to the overall genetic risk burden for BD rather 
than to lithium per se. To assess this, we reevaluated the association between the most 
significant SNPs in a model that corrected for differences in overall BD risk burden (Risk 
Profile Score, RPS) in the European-ancestry samples. Similar results were obtained (Table 
S6, Supplementary Materials). The four SNPs on chromosome 21 continued to show 
genome-wide significant association with lithium response. There was also no detectable 
relationship between RPS and Alda Score in this sample (data not shown). These results 
demonstrate that the findings are specific to lithium response, and do not reflect genetic risk 
for BD.
We assessed genetic association of lithium response in the subset of patients diagnosed with 
bipolar I disorder. This narrower phenotype comprised about 79% of all participants. Results 
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showed robust association of the same four SNPs on chromosome 21 with the continuous 
lithium response trait, suggesting that these SNPs play a role in lithium response in subjects 
with more narrowly defined BD.
Retrospective assessment of lithium response, while reliable in previous studies and when 
assessed within ConLiGen23, is limited by recall bias, incomplete information, and other 
sources of unmeasured variance. To evaluate the potential impact of these sources of error 
and test the identified SNPs in an independent sample, we genotyped all four SNPs in 
samples of BD patients treated with lithium monotherapy and assessed prospectively. The 
sample was recruited entirely from the San Diego Veterans Affairs Medical Center. A total 
of 89 bipolar disorder patients participated in the prospective study. After screening for 
eligibility and initial assessment, patients were started on lithium and entered the 
stabilization phase. The goal in this phase was to stabilize patients within three months on 
lithium monotherapy. Following this, patients were observed for one month to assure 
stabilization after discontinuation of other medications. Patients then entered the 
maintenance phase and were followed at two to four month intervals for two years. Basic 
characteristics of this sample can be found in Table S7 (for details on genotyping and 
statistical analysis, see Supplementary Materials). After excluding 16 subjects due to 
screening failure, diagnosis change, voluntary withdrawal, and non-compliance, 73 bipolar 
patients (BPI:65, BPII:8) were used for the final data analyses.
After correction for several factors known to influence relapse (see Supplementary 
Materials.) heterozygote carriers of the alleles associated with poorer lithium response 
showed a significantly higher rate of relapse compared to carriers of the alternate alleles 
(p=0·03, hazard ratio = 3·8; Figure S5 & table S8).
DISCUSSION
This is the largest GWAS of lithium response in BD published to date. In a sample of more 
than 2500 individuals, we detected genome-wide significant evidence of association with 
SNPs at a locus on chromosome 21. Further support for this finding was detected in a small, 
independent, prospectively ascertained sample of patients on lithium monotherapy. The 
associated locus is thought to encode two long, non-coding RNA genes. This finding could 
have important implications for our understanding of lithium’s mechanism of action in BD. 
Replication in independent samples is needed. Personal treatment planning based on genetic 
data depends on identification of additional markers and their total contribution to 
differences between individuals in response to treatment. Detection of genome-wide 
significant markers for a phenotype is the first step in demonstrating if such a goal is 
achievable.
This study has several limitations. ConLiGen relies on retrospective ratings of treatment 
response, which lack precision and are subject to recall bias. However, response was rated 
using a well-validated instrument12, previously shown to be reliable by members of the 
ConLiGen Consortium23, and the results were supported in a prospectively assessed, 
independent sample. The ConLiGen sample encompassed a variety of patients from a range 
of ancestries and clinical settings. This is more representative of real-world clinical 
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situations, where patients present at various stages of BD and with a range of illness severity 
and underlines the robustness of our results. As for any GWAS of a complex trait, sample 
size is critical. The ConLiGen sample size appears small when compared to GWAS of 
categorical disease phenotypes, where samples on the order of 10,000 are often required. 
However, common alleles have been found to exert larger effects upon pharmacogenomic 
traits30, 31, where samples of 2500 cases are relatively large. On the other hand, the 
statistically significant excess agreement in the direction of association between GWAS 1 
and GWAS 2 that we observed suggests that additional genome-wide significant associations 
might emerge from larger sample sizes.
Our results do not support previous reports of individual genes strongly associated with 
lithium response16, 18. Some of those reports were based on smaller samples that may not be 
comparable to those we studied. They may also represent false positives. Much larger 
sample sizes would be needed to exclude any particular genes in a GWAS, however.
The main findings seem to implicate lncRNA genes. This implication is causally uncertain, 
since we have not yet linked allelic variation at the associated SNPs to expression or 
function of either transcript. There has been an increasing appreciation of the role of 
lncRNAs in gene regulation, especially in the CNS. An ongoing study of gene expression in 
peripheral blood during and after acute episodes of BD found a trend toward decreased 
expression of one of the lncRNAs identified within the association region (AL157359.3; 
p=0·08, fold change=1·17) after an acute manic episode (Po-Hsiu Kuo, personal 
communication, 12/2014).
Even if confirmed, the clinical importance of these findings may be limited. The relatively 
low frequency of the response-associated alleles means that genetic testing would be 
uninformative in most patients. These and additional genetic markers from future studies 
could ultimately lead to a clinically informative test, but additional information from 
established predictors such as family history may be needed, as has been observed for other 
phenotypes32. In line with similar approaches in the field, polygenic score analyses to 
predict lithium response may prove to be especially informative, provided that larger, 
adequately phenotyped samples become available. Clinical utility is a high bar, but the 
current dearth of good biomarkers of lithium response means that any robust genetic markers 
could constitute a real step forward.
Any GWAS is subject to experimental error. Type I error can occur, although stringent levels 
of genome-wide significance keep this to a minimum. Association findings might reflect 
unobserved variables. The alleles found to be associated with poor lithium response in this 
study could actually reflect something else, such as treatment adherence. Supportive results 
in a longitudinal, prospectively-rated sample are encouraging, but due to distinct methods of 
rating lithium response this cannot be viewed as a replication of the ConLiGen results. On 
the other hand, relapse over the course of two years on lithium monotherapy is in some ways 
a better phenotype than that assessed by the Alda Scale, which relies on retrospective 
ratings. The fact that the same alleles were associated with both retrospective response and 
prospective relapse may actually increase the importance of the findings and their potential 
clinical relevance.
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GWAS are best viewed as an important starting point for additional investigations. Before 
embarking on functional studies, future work will need to replicate and extend these findings 
using comparable ratings of lithium response in large samples. As we may have missed 
some additional true positive markers due to power constraints, such studies should also 
target the longer list of SNPs that were associated with lithium response at less significant p-
values than were formally reported here. Summary results for SNPs with p values <5x10−5 
are posted at www.conligen.org; the corresponding authors can be contacted for more 
complete summary results. Additional experimental work is needed to establish the 
functional SNP(s) and their biological impact, if any, in cellular or animal models. Such 
models could facilitate screening for other drugs that mimic lithium, thus generating novel 
therapeutic candidates suitable for further study.
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RESEARCH IN CONTEXT
Evidence before this study
Lithium is a mainstay in the treatment of bipolar disorder (BD), also known as manic-
depressive illness, and may exert neuroprotective effects in neurodegenerative disorders. 
However, little is known about lithium’s mechanism of action. Individual response in BD 
varies from excellent to very poor, with about 30% of patients considered good 
responders7–9. Many genetic association studies of lithium response have been 
performed, but samples were small, and replicable findings have not emerged14, 15. Three 
genome-wide association studies (GWAS) of lithium response have been published to 
date, each implicating different loci.16–18
Added value of this study
The international Consortium on Lithium Genetics (www.ConLiGen.org) has assembled 
the largest GWAS on lithium response in BD to date, totaling over 2,500 individuals. We 
now present genome-wide significant evidence of association between lithium response 
and common genetic variants on chromosome 21. The genetic region associated with 
response contains two long non-coding RNA genes, which are increasingly appreciated 
as important regulators of gene expression, particularly in the CNS. These findings 
suggest a novel potential mechanism of action for lithium. In an independent, 
prospectively followed clinical sample, the identified genetic markers also helped predict 
relapse during lithium treatment.
Implications of all the available evidence
This study suggests that a better understanding of drug mechanisms and response can be 
achieved through international cooperative efforts that leverage clinical expertise with 
large-scale genomics. The genetic markers identified here show predictive value in a 
prospective clinical sample, but further studies are needed to establish the potential 
clinical utility of these findings and their biological context. Confirmed biomarkers of 
lithium response would constitute an important step forward in the clinical management 
of BD.
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Figure 1. 
Meta-analysis results of dichotomous and continuous lithium response phenotypes in all 
participants (CEU plus Asian samples). Genome-wide significant association can be 
detected with the continuous phenotype. SNPs in green are in linkage disequilibrium 
(r2>0·6) with the index SNPs (rs74795342).
Hou et al. Page 16
Lancet. Author manuscript; available in PMC 2017 March 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Regional association plot of the region on chromosome 21 in which the genome-wide 
significant SNPs are located. Imputation quality for the top 4 SNPs was excellent (Table S3, 
Supplementary Materials).
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Figure 3. 
Forest plots for the most significant SNP, rs74795342. [Panel A, dichotomous phenotype; 
Panel B, continuous phenotype].
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Table 1
Phenotypic characteristics of individuals used for the analyses
GWAS 1 GWAS 2
All subjects
N 1162 1401
Percent female 59·30 56·17
Age at interview 47·80 (13·99) 46·84 (13·83)
ALDA scale A score 6·03 (3·14) 6·35 (2·90)
ALDA scale total B score 2·11 (1·63) 2·86 (1·68)
ALDA scale total score 4·29 (3·32) 3·90 (3·02)
Dichotomous phenotype: Good response (ALDA scale total score 7 or greater)
N 361 342
Age at interview 51·72 (14·27) 48·92 (14·80)
Percent female 56·23 51·75
ALDA scale A score 9·21 (0·82) 9·36 (0·77)
ALDA scale total B score 0·88 (0·84) 1·38 (0·96)
ALDA scale total score 8·33 (1·10) 7·99 (1·01)
Dichotomous phenotype: Poor response (ALDA scale total score 6 or less)
N 801 1059
Age at interview 45·86 (13·44) 46·17 (13·44)
Percent female 60·67 57·60
ALDA scale A score 4·60 (2·71) 5·38 (2·66)
ALDA scale total B score 2·66 (1·59) 3·34 (1·58)
ALDA scale total score 2·47 (2·19) 2·58 (2·14)
Continuous phenotype (ALDA scale A score, all subjects with a total B score greater 4 excluded)
N 1065 1168
Age at interview 48·12 (14·00) 46·97 (13·84)
Percent female 59·91 56·34
ALDA scale A score 6·13 (3·13) 6·52 (2·87)
ALDA scale total B score 1·78 (1·26) 2·35 (1·16)
ALDA scale total score 4·59 (3·28) 4·40 (2·94)
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